Table 4.
Secondary Outcomes
| Characteristic | Control | Intervention | NNT | P Value |
|---|---|---|---|---|
| CRQ emotional function | ||||
| Month 6 change from baseline, mean (SD) | 0.10 (1.0) | 0.50 (1.0) | 0.004 | |
| Month 12 change from baseline, mean (SD) | 0.15 (0.9) | 0.43 (1.0) | 0.058 | |
| Improved more than MCID at 6 mo, % | 14.1 | 29.9 | 6 | 0.018 |
| Improved more than MCID at 12 mo, % | 14.3 | 28.8 | 6 | 0.036 |
| CRQ physical function | ||||
| Month 6 change from baseline, mean (SD) | −0.01 (1.0) | 0.33 (0.9) | 0.036 | |
| Month 12 change from baseline, mean (SD) | −0.04 (1.0) | 0.27 (1.0) | 0.016 | |
| Improved more than MCID at 6 mo, % | 12.8 | 26.0 | 7 | 0.038 |
| Improved more than MCID at 12 mo, % | 11.4 | 19.2 | 0.199 | |
| Physical activity level change at Month 6 | 0.01 | 0.01 | NS | |
| Physical activity level change at Month 12 | 0.01 | −0.10 | NS | |
| Died in first 12 mo, n (%) | 12 (11.3%) | 10 (9.3%) | 0.620 | |
| Patient-reported prednisone/antibiotic use, n (%) | ||||
| Baseline to Month 3 | 40 (46.5%) | 51 (56.7%) | 0.178 | |
| Month 3 to Month 6 | 37 (44.0%) | 46 (51.1%) | 0.351 | |
| Month 6 to Month 9 | 35 (43.2%) | 49 (57.6%) | 0.063 | |
| Month 9 to Month 12 | 34 (43.0%) | 54 (65.9%) | 0.004 | |
| Any use in first 12 mo | 64 (68.8%) | 83 (87.4%) | 0.002 |
Definition of abbreviations: CRQ = Chronic Respiratory Disease Questionnaire; MCID = minimal clinically important difference, NNT = number needed to treat, NS = nonsignificant.